Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Orphazyme A/S
  6. News
  7. Summary
    ORPHA   DK0060910917

ORPHAZYME A/S

(ORPHA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Orphazyme A/S : Guggenheim Downgrades Orphazyme to Sell From Neutral

06/21/2021 | 08:42am EDT


ę MT Newswires 2021
All news about ORPHAZYME A/S
10/19Pharnext renforce son équipe de direction avec trois nominations clés pour poursuivre l..
DJ
10/19Pharnext strengthens its management team with three key appointments to support ongoing..
DJ
10/18European ADRs Move Lower in Monday Trading
MT
10/14European ADRs Climb Higher in Thursday Trading
MT
10/08European ADRs Move Higher in Friday Trading
MT
10/07ORPHAZYME A/S : Modified long-term share-based incentive program for 2021 (Form 6-K)
PU
10/07ORPHAZYME A/S : Modified long-term share-based incentive program for 2021
AQ
10/05ORPHAZYME A/S : provides regulatory and financial updates (Form 6-K)
PU
10/05ORPHAZYME A/S : Says European Review of Arimoclomol Underway; Raises 2021 Cash Position Ou..
MT
10/05ORPHAZYME A/S : provides regulatory and financial updates
AQ
More news
Analyst Recommendations on ORPHAZYME A/S
More recommendations
Financials
Sales 2021 24,4 M 3,80 M 3,80 M
Net income 2021 -634 M -99,0 M -99,0 M
Net cash 2021 122 M 19,1 M 19,1 M
P/E ratio 2021 -1,71x
Yield 2021 -
Capitalization 921 M 143 M 144 M
EV / Sales 2021 32,8x
EV / Sales 2022 28,9x
Nbr of Employees 180
Free-Float 98,6%
Chart ORPHAZYME A/S
Duration : Period :
Orphazyme A/S Technical Analysis Chart | ORPHA | DK0060910917 | MarketScreener
Technical analysis trends ORPHAZYME A/S
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 26,34 DKK
Average target price 60,50 DKK
Spread / Average Target 130%
EPS Revisions
Managers and Directors
Christophe Bourdon Chief Executive Officer
Anders Fink Vadsholt Chief Financial Officer
Georges Gemayel Chairman
Thomas Kirkegaard Jensen Chief Scientific Officer
Claus BornŠs Senior Manager-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ORPHAZYME A/S-60.75%143
GILEAD SCIENCES, INC.16.25%84 921
BIONTECH SE258.67%70 618
WUXI APPTEC CO., LTD.23.63%64 231
REGENERON PHARMACEUTICALS22.57%61 565
VERTEX PHARMACEUTICALS-22.12%47 753